The RATIO: Registry of Infections and Lymphoma in Patients Treated With TNF-a Antagonists
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The RATIO registry is a French registry designed by a multidisciplinary group to collect data
on opportunistic and severe bacterial infections and lymphoma in patients treated with TNF-a
antagonists ( infliximab, etanercept and adalimumab). A total of 486 medical units in
metropolitan France participate in the RATIO registry. All diagnosis are retained after
validation by 2 qualified infectious disease or haematologist physicians (on the basis of the
standardized case report form, the hospitalisation summary, and the microbiological and
radiological results). Risk factors for developing these conditions when treated by TNF-a
antagonists will be identified in a case control study. Incidence of these diseases will be
calculated.